MA46436A - Compositions comprenant de la relaxine et leurs méthodes d'utilisation - Google Patents
Compositions comprenant de la relaxine et leurs méthodes d'utilisationInfo
- Publication number
- MA46436A MA46436A MA046436A MA46436A MA46436A MA 46436 A MA46436 A MA 46436A MA 046436 A MA046436 A MA 046436A MA 46436 A MA46436 A MA 46436A MA 46436 A MA46436 A MA 46436A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- compositions including
- including relaxin
- relaxin
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2221—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/005—Medical syringes, e.g. enemata; Irrigators comprising means for injection of two or more media, e.g. by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/07—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662405795P | 2016-10-07 | 2016-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA46436A true MA46436A (fr) | 2019-08-14 |
Family
ID=60186382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046436A MA46436A (fr) | 2016-10-07 | 2017-10-09 | Compositions comprenant de la relaxine et leurs méthodes d'utilisation |
Country Status (7)
Country | Link |
---|---|
US (2) | US11723957B2 (fr) |
EP (2) | EP4056196A1 (fr) |
AU (1) | AU2017339536A1 (fr) |
CA (1) | CA3078452A1 (fr) |
DK (1) | DK3522911T3 (fr) |
MA (1) | MA46436A (fr) |
WO (1) | WO2018068047A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3580232B1 (fr) | 2017-02-08 | 2023-09-20 | Bristol-Myers Squibb Company | Polypeptides de relaxine modifiés comprenant un activateur pharmacocinétique et leurs utilisations |
JP2023526512A (ja) * | 2020-05-22 | 2023-06-21 | トラスティーズ オブ ボストン ユニバーシティ | 線維化疾患を処置するための方法および組成物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69001248T2 (de) | 1989-05-04 | 1993-10-14 | Genentech Inc | Verfahren und zusammensetzungen zur isolation von menschlichem relaxin. |
US6251863B1 (en) * | 1998-09-08 | 2001-06-26 | Samuel K. Yue | Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin |
ITFI20030328A1 (it) * | 2003-12-24 | 2005-06-25 | Mario Bigazzi | Uso della relaxina come adiuvante nella differenziazione |
US20080269762A1 (en) * | 2007-04-25 | 2008-10-30 | Biomet Manufacturing Corp. | Method and device for repair of cartilage defects |
US8735539B2 (en) * | 2010-08-17 | 2014-05-27 | Ambrx, Inc. | Relaxin polypeptides comprising non-naturally encoded amino acids |
US8404268B2 (en) | 2010-10-26 | 2013-03-26 | Kyphon Sarl | Locally targeted anti-fibrotic agents and methods of use |
WO2015067791A1 (fr) * | 2013-11-11 | 2015-05-14 | Ascendis Pharma Relaxin Division A/S | Promédicaments à bae de relaxine |
MX370115B (es) * | 2014-07-30 | 2019-12-02 | Ngm Biopharmaceuticals Inc | Dímeros que comprenden dos polipéptidos, útiles en el tratamiento de trastornos metabólicos. |
EP4011919A3 (fr) | 2015-12-09 | 2022-10-12 | The Scripps Research Institute | Protéines de fusion d'immunoglobuline de relaxine et procédés d'utilisation |
-
2017
- 2017-10-09 DK DK17791235.9T patent/DK3522911T3/da active
- 2017-10-09 US US16/339,659 patent/US11723957B2/en active Active
- 2017-10-09 WO PCT/US2017/055799 patent/WO2018068047A1/fr unknown
- 2017-10-09 MA MA046436A patent/MA46436A/fr unknown
- 2017-10-09 EP EP21212781.5A patent/EP4056196A1/fr active Pending
- 2017-10-09 EP EP17791235.9A patent/EP3522911B1/fr active Active
- 2017-10-09 CA CA3078452A patent/CA3078452A1/fr active Pending
- 2017-10-09 AU AU2017339536A patent/AU2017339536A1/en active Pending
-
2023
- 2023-06-28 US US18/215,317 patent/US20240173383A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240173383A1 (en) | 2024-05-30 |
EP3522911B1 (fr) | 2021-12-08 |
AU2017339536A1 (en) | 2019-05-23 |
WO2018068047A8 (fr) | 2019-03-21 |
EP3522911A1 (fr) | 2019-08-14 |
EP4056196A1 (fr) | 2022-09-14 |
CA3078452A1 (fr) | 2018-04-12 |
US11723957B2 (en) | 2023-08-15 |
US20190282665A1 (en) | 2019-09-19 |
DK3522911T3 (da) | 2022-03-07 |
WO2018068047A1 (fr) | 2018-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
MA44955A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
MA49288A (fr) | Reactifs particulaires oligomères et leurs méthodes d'utilisation | |
MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
MA46481A (fr) | Compositions d'oligonucléotides et méthodes associées | |
MA48595A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA44526A (fr) | Oxystérols et leurs méthodes d'utilisation | |
MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
MA42302A (fr) | Lactames bicycliques et leurs méthodes d'utilisation | |
MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA42446A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
MA42409A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA44081A (fr) | Anticorps anti-c5 et leurs procédés d'utilisation | |
MA43385A (fr) | Nouveaux anticorps anti-claudine et méthodes d'utilisation |